Supporting People-Centered Hepatitis B Care
In a new fact sheet, TREAT Asia provides a guide to the latest gold-standard approaches to chronic hepatitis B prevention, care, diagnosis, and treatment
The World Health Organization (WHO) estimates 254 million people are living with hepatitis B virus (HBV) infection globally. HBV-associated mortality is trending upwards, with 1.1 million deaths in 2022 compared to 820,000 in 2019.
Earlier this year, the WHO updated its guidelines for the prevention, care, diagnosis, and treatment of people living with and at risk for HBV infection.
In concert with WHO’s aims, amfAR’s TREAT Asia program has created a fact sheet that summarizes the primary messages and recommendations to help policymakers and healthcare providers in low- and middle-income countries strengthen their efforts to address HBV and related national responses. The guidelines can also be used by civil society and community organizations to advocate for access to prevention, diagnosis, and treatment of HBV.
In addition, the fact sheet spotlights the Asia-Pacific region, where 154 million people, or 62% of the global total, are living with chronic HBV. In addition, 67% of HBV-related deaths occurred in the region in 2022. To advance toward the elimination of HBV by 2030, national programs in the region need to rapidly expand screening, vaccination, diagnosis, and treatment of HBV through the adoption of the updated guidelines.
Read the fact sheet here.
Share This:
